新華醫療(600587.SH):子公司擬參設惠遠華檢 圍繞體外診斷行業進行股權投資
格隆匯 8 月 3日丨新華醫療(600587.SH)公佈,為推進新華醫療在體外診斷行業的戰略佈局,新華醫療全資子公司華佗國際擬與國惠改革基金、上海威士達共同作為有限合夥人參與設立惠遠華檢醫學檢驗股權投資合夥企業(有限合夥)(惠遠華檢),由中民惠遠作為普通合夥人暨執行事務合夥人,惠遠華檢總募集規模為人民幣3.001億元,其中國惠改革基金認繳出資1.5億元、華佗國際認繳出資9000萬元、上海威士達認繳出資6000萬元、中民惠遠認繳出資10萬元。國惠改革基金、華佗國際、上海威士達認繳出資額將按照惠遠華檢合夥協議約定分批實繳到位。
合夥企業將圍繞體外診斷行業進行股權投資,重點關注微生物檢測、分子診斷、其他創新型IVD技術產品等細分領域,包括但不限於併購投資。
設立惠遠華檢,可以藉助執行事務合夥人的經驗、能力和資源,引進體外診斷行業先進技術及產品,為新華醫療和上海威士達發掘、孵化、培育優質項目,促進新華醫療在體外診斷細分領域全產業鏈上的戰略佈局。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.